

SOLTA MEDICAL INC  
Form 8-K  
January 28, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**January 27, 2013**

**Date of Report (date of earliest event reported)**

**SOLTA MEDICAL, INC.**

**(Exact name of Registrant as specified in its charter)**

Edgar Filing: SOLTA MEDICAL INC - Form 8-K

(State or other jurisdiction of  
incorporation or organization)

(Commission  
File Number)  
**25881 Industrial Boulevard, Hayward, California 94545**

(I.R.S. Employer  
Identification Number)

(Address of principal executive offices)

**(510) 782-2286**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On January 27, 2013, William Brodie advised Solta Medical, Inc. that he resigned from his position as Vice President of Global Sales. Mr. Brodie's role will be assumed by our President, Chief Executive Officer and Chairman, Stephen J. Fanning. Mr. Brodie has agreed to serve as a consultant for a period of 90 days to assist us in achieving an effective transition of his responsibilities.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SOLTA MEDICAL, INC.**

Date: January 28, 2013

By: /s/ John F. Glenn  
John F. Glenn  
Chief Financial Officer